{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:20:57Z","timestamp":1780442457990,"version":"3.54.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vaccine.2022.02.043","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T17:11:35Z","timestamp":1645809095000},"page":"1932-1947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Epidemiology and economic burden of meningococcal disease in Germany: A systematic review"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5291-650X","authenticated-orcid":false,"given":"S.","family":"Gruhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-323X","authenticated-orcid":false,"given":"J.","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9552-6969","authenticated-orcid":false,"given":"W.","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Damm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dietzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Knuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.02.043_b0005","unstructured":"European Centre for Disease Prevention and Control. Factsheet about meningococcal disease: ECDC; 2019 [cited 2021 February 1] Available from: URL: https:\/\/www.ecdc.europa.eu\/en\/meningococcal-disease\/factsheet."},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.043_b0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1574-6976.2006.00052.x","article-title":"Lessons from meningococcal carriage studies","volume":"31","author":"Caugant","year":"2007","journal-title":"FEMS Microbiol Rev"},{"issue":"12","key":"10.1016\/j.vaccine.2022.02.043_b0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.02.043_b0020","unstructured":"World Health Organisation. Meningococcal meningitis; 2018 [cited 2021 February 1] Available from: URL: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/meningococcal-meningitis."},{"issue":"21","key":"10.1016\/j.vaccine.2022.02.043_b0025","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.02.043_b0030","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: Clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.02.043_b0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.13105\/wjma.v4.i4.77","article-title":"Antibiotics for eradicating meningococcal carriages: Network meta-analysis and investigation of evidence inconsistency","volume":"4","author":"Abdelhamid","year":"2016","journal-title":"WJMA (World J Meta-Anal)"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.043_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2017.04.007","article-title":"Meningococcal disease in the Middle East and Africa: Findings and updates from the Global Meningococcal Initiative","volume":"75","author":"Borrow","year":"2017","journal-title":"J Infect"},{"issue":"48","key":"10.1016\/j.vaccine.2022.02.043_b0045","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1016\/j.vaccine.2016.10.022","article-title":"Meningococcal disease in the Asia-Pacific region: Findings and recommendations from the Global Meningococcal Initiative","volume":"34","author":"Borrow","year":"2016","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.043_b0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40121-019-0254-1","article-title":"Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review","volume":"8","author":"Presa","year":"2019","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.043_b0055","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/JCM.05385-11","article-title":"Genotypic and Phenotypic Characterization of Carriage and Invasive Disease Isolates of Neisseria meningitidis in Finland","volume":"50","author":"Jounio","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.043_b0060","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1128\/JCM.01322-10","article-title":"Persistence, Replacement, and Rapid Clonal Expansion of Meningococcal Carriage Isolates in a 2008 University Student Cohort","volume":"49","author":"Bidmos","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2022.02.043_b0065","unstructured":"European Centre for Disease Prevention and Control. Invasive meningococcal disease: Annual epidemiological report for 2017. Stockholm: ECDC; 2019."},{"issue":"16","key":"10.1016\/j.vaccine.2022.02.043_b0070","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2022.02.043_b0075","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1080\/21645515.2015.1051276","article-title":"Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013","volume":"11","author":"Br\u00f6ker","year":"2015","journal-title":"Human Vaccines Immunotherapeutics"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.043_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025691","article-title":"Communicable diseases prioritized for surveillance and epidemiological research: results of a standardized prioritization procedure in Germany, 2011","volume":"6","author":"Balabanova","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.043_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2022.02.043_b0090","unstructured":"Robert Koch-Institut. \u201cInvasive Meningokokken- Erkrankungen 2012\u2009\u2013\u20092015\u201c. Berlin: RKI-Bib1 (Robert Koch-Institut): Robert Koch-Institut; 2016. Epidemiologisches Bulletin 43."},{"key":"10.1016\/j.vaccine.2022.02.043_b0095","unstructured":"Statistisches Bundesamt. Bev\u00f6lkerung: Bundesl\u00e4nder, Stichtag, Altersjahre: Tabelle 12411\u20130006. Wiesbaden: Statistisches Bundesamt; 2020."},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.043_b0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jinf.2012.09.008","article-title":"Epidemiology of invasive meningococcal disease in Germany, 2002\u20132010, and impact of vaccination with meningococcal C conjugate vaccine","volume":"66","author":"Hellenbrand","year":"2013","journal-title":"J Infect"},{"issue":"8","key":"10.1016\/j.vaccine.2022.02.043_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160126","article-title":"Risk of Invasive Meningococcal Disease in Men Who Have Sex with Men: Lessons Learned from an Outbreak in Germany, 2012\u20132013","volume":"11","author":"Hellenbrand","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.043_b0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2807\/1560-7917.ES.2016.21.5.30122","article-title":"Evaluation of a temporary vaccination recommendation in response to an outbreak of invasive meningococcal serogroup C disease in men who have sex with men in Berlin, 2013\u20132014","volume":"21","author":"Koch","year":"2016","journal-title":"Euro Surveill"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.043_b0115","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-2006-927077","article-title":"Meningokokken-Tr\u00e4gerstatus von Gymnasiasten und m\u00f6gliche Risikofaktoren","volume":"68","author":"Oppermann","year":"2006","journal-title":"Gesundheitswesen"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.043_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228020","article-title":"Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database","volume":"15","author":"Huang","year":"2020","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vaccine.2022.02.043_b0125","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.vaccine.2019.01.013","article-title":"The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany","volume":"37","author":"Scholz","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.02.043_b0130","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s001120050090","article-title":"Hautblutungen und Prognose bei systemischen Infektionen durch Neisseria meningitidis in Deutschland","volume":"144","author":"N\u00fcrnberger","year":"1996","journal-title":"Monatsschrift Kinderheilkunde"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2022.02.043_b0135","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1007\/PL00014354","article-title":"Systemic meningococcal infection: which children may benefit from adjuvant haemostatic therapy? Results from an observational study","volume":"158","author":"N\u00fcrnberger","year":"1999","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.043_b0140","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-015-1693-6","article-title":"Public health management of invasive meningococcal disease in Baden-Wuerttemberg, Germany, 2012: adherence to guidance and estimation of resources required as determined in a survey of local health authorities","volume":"15","author":"Murajda","year":"2015","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.043_b0145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4161\/hv.20098","article-title":"Increase of meningococcal serogroup Y cases in Europe: a reason for concern?","volume":"8","author":"Br\u00f6ker","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2022.02.043_b0150","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.4161\/hv.21794","article-title":"Meningococcal serogroup Y emergence in Europe: update 2011","volume":"8","author":"Br\u00f6ker","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.043_b0155","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.4161\/hv.28206","article-title":"Meningococcal serogroup Y emergence in Europe: high importance in some European regions in 2012","volume":"10","author":"Br\u00f6ker","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.043_b0160","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3201\/eid1603.091102","article-title":"Vaccine preventability of meningococcal clone, Greater Aachen Region, Germany","volume":"16","author":"Elias","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.043_b0165","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1017\/S0950268899003416","article-title":"Serogroup C meningococcal disease outbreak associated with discotheque attendance during carnival","volume":"124","author":"Hauri","year":"2000","journal-title":"Epidemiol. Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2022.02.043_b0170","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1055\/s-2005-858899","article-title":"Cluster von Meningokokkenerkrankungen im Allg\u00e4u - Interventionsstrategien","volume":"67","author":"Hautmann","year":"2005","journal-title":"Gesundheitswesen"},{"issue":"14","key":"10.1016\/j.vaccine.2022.02.043_b0175","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.14.1800245","article-title":"Increase of invasive meningococcal serogroup W disease in Europe","volume":"24","author":"Krone","year":"2019","journal-title":"Euro Surveill"},{"issue":"25","key":"10.1016\/j.vaccine.2022.02.043_b0180","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.25.1900565","article-title":"Recurrent invasive meningococcal infections - quantifying the risk, Germany, 2002 to 2018","volume":"25","author":"Krone","year":"2020","journal-title":"Euro Surveill"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.02.043_b0185","first-page":"S13","article-title":"Surveillance meldepflichtiger Infektionskrankheiten in Bayern - Ergebnisse 2002","volume":"66","author":"Ludwig","year":"2004","journal-title":"Gesundheitswesen"},{"key":"10.1016\/j.vaccine.2022.02.043_b0190","doi-asserted-by":"crossref","unstructured":"Marcus U, Vogel U, Schubert A, et al. A cluster of invasive meningococcal disease in young men who have sex with men in Berlin, October 2012 to May 2013. Infektionsepidemiologie: Robert Koch-Institut; 2013.","DOI":"10.2807\/1560-7917.ES2013.18.28.20523"},{"issue":"4","key":"10.1016\/j.vaccine.2022.02.043_b0195","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1017\/S0950268806007151","article-title":"Capture\u2013recapture analysis to estimate the incidence of invasive meningococcal disease in Germany, 2003","volume":"135","author":"Schrauder","year":"2007","journal-title":"Epidemiol Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.043_b0200","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1017\/S0950268817002771","article-title":"Sex- and age patterns in incidence of infectious diseases in Germany: analyses of surveillance records over a 13-year period (2001\u20132013)","volume":"146","author":"Walter","year":"2018","journal-title":"Epidemiol Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.043_b0205","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1055\/s-2002-32177","article-title":"Surveillance-System zur Erfassung zentralnerv\u00f6ser Infektionen in Niedersachsen 1998\u20132000","volume":"64","author":"Beyrer","year":"2002","journal-title":"Gesundheitswesen"},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.043_b0210","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-2007-1025344","article-title":"Meningitis bei 154 Kindern einer Kinderklinik in Deutschland: Klinische und epidemilogische Aspekte","volume":"204","author":"Hensel","year":"1992","journal-title":"Klin Padiatr"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.043_b0215","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00431-007-0651-4","article-title":"Secular trends in pediatric bloodstream infections over a 20-year period at a tertiary care hospital in Germany","volume":"167","author":"Hufnagel","year":"2008","journal-title":"Eur J Pediatr"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.043_b0220","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF01709456","article-title":"Predisposing conditions and pathogens in bacteremia in hospitalized children","volume":"17","author":"Berner","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.043_b0225","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0034-1398690","article-title":"Septic shock in children in an urban area in Western Germany\u2013outcome, risk factors for mortality and infection epidemiology","volume":"227","author":"Breuling","year":"2015","journal-title":"Klin Padiatr"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.043_b0230","doi-asserted-by":"crossref","first-page":"R281","DOI":"10.1186\/cc10565","article-title":"Arterial cerebrovascular complications in 94 adults with acute bacterial meningitis","volume":"15","author":"Klein","year":"2011","journal-title":"Crit Care"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2022.02.043_b0235","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1099\/00221287-148-6-1813","article-title":"Many carried meningococci lack the genes required for capsule synthesis and transport","volume":"148","author":"Claus","year":"2002","journal-title":"Microbiology (Reading)"},{"issue":"8","key":"10.1016\/j.vaccine.2022.02.043_b0240","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1086\/428590","article-title":"Genetic Analysis of Meningococci Carried by Children and Young Adults","volume":"191","author":"Claus","year":"2005","journal-title":"J INFECT DIS"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.043_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212052","article-title":"Asymptomatic carriage of Neisseria meningitidis, Haemophilus influenzae, Streptococcus pneumoniae, Group A Streptococcus and Staphylococcus aureus among adults aged 65 years and older","volume":"14","author":"Dray\u00df","year":"2019","journal-title":"PLoS One"},{"issue":"3-4","key":"10.1016\/j.vaccine.2022.02.043_b0250","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijheh.2007.05.006","article-title":"Longitudinal study of meningococcal carrier rates in teenagers","volume":"211","author":"Glitza","year":"2008","journal-title":"Int J Hyg Environ Health"},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.043_b0255","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s150100050070","article-title":"Six Different Strains of Neisseria meningitidis in a Case with meningococcal Sepsis and Five Contact Persons in a Boys' Home","volume":"28","author":"Linde","year":"2000","journal-title":"Infection"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.043_b0260","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/00006454-199310000-00002","article-title":"Deafness, complement deficiencies and immunoglobulin status in patients with meningococcal diseases due to uncommon serogroups","volume":"12","author":"Mayatepek","year":"1993","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.043_b0265","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00103-020-03150-7","article-title":"Meldepflichten f\u00fcr Infektionskrankheiten und Infektionserreger in Deutschland: Entwicklung und Verbesserungsvorschl\u00e4geMandatory notification of infectious diseases and agents in Germany: development and suggestions for improvement","volume":"63","author":"Heudorf","year":"2020","journal-title":"Bundesgesundheitsbl"},{"key":"10.1016\/j.vaccine.2022.02.043_b0270","unstructured":"Gesetz zur Verh\u00fctung und Bek\u00e4mpfung von Infektionskrankheiten beim Menschen: Infektionsschutzgesetz - IfSG 2000 Jul 20."},{"key":"10.1016\/j.vaccine.2022.02.043_b0275","unstructured":"Robert Koch-Institut. Stellungnahme der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut (RKI) zum Stand der Bewertung desneuen Meningokokken-B-Impfstoffs Bexsero\u00ae. Berlin: Robert Koch-Institut; 2013. Epidemiologisches Bulletin 49."},{"key":"10.1016\/j.vaccine.2022.02.043_b0280","unstructured":"Robert Koch-Institut. Empfehlungen der St\u00e4ndigen Empfehlungen der St\u00e4ndigen Impfkommission beim Robert Koch-Institut 2020\/2021. Berlin: Robert Koch-Institut; 2020. Epidemiologisches Bulletin 34."},{"key":"10.1016\/j.vaccine.2022.02.043_b0285","unstructured":"Robert Koch-Institut. Aktualisierung der Meningokokken-Impfempfehlung: Aktualisierung der Meningokokken-Impfempfehlung:Anwendung des Meningokokken-B-Impfstoffs bei Personen mit erh\u00f6htem Risiko f\u00fcr Meningokokken-Erkrankungen: Wissenschaftliche Begr\u00fcndung: Robert Koch-Institut; 2015. Epidemiologisches Bulletin 37."},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.043_b0290","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.043_b0295","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2022.02.043_b0300","unstructured":"Robert Koch-Institut. Impfstatus der Kinder und Jugendlichen in Deutschland, STIKO: Influenzaimpfungen in der COVID-19-Pandemie. Berlin: Robert Koch-Institut; 2020. Epidemiologisches Bulletin 32\/33."},{"key":"10.1016\/j.vaccine.2022.02.043_b0305","unstructured":"Robert Koch-Institut. Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Virushepatitis C im Jahr 2012. Berlin: Robert Koch-Institut; 2013. Epidemiologisches Bulletin 30."},{"issue":"16","key":"10.1016\/j.vaccine.2022.02.043_b0310","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.16.18-00158","article-title":"Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018","volume":"23","author":"Knol","year":"2018","journal-title":"Eurosurveillance"},{"issue":"20","key":"10.1016\/j.vaccine.2022.02.043_b0315","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.20.17-00474","article-title":"Establishment of the European meningococcal strain collection genome library (EMSC-GL) for the 2011 to 2012 epidemiological year","volume":"23","author":"Bratcher","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2022.02.043_b0320","first-page":"1","article-title":"Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations","author":"Martin\u00f3n-Torres","year":"2021","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.vaccine.2022.02.043_b0325","unstructured":"Centrum f\u00fcr Reisemedizin. Kostenerstattung: Reiseimpfungen; 2020. Available from: URL: https:\/\/www.crm.de\/krankenkassen\/kk_tabelle_kassen.htm."},{"issue":"29","key":"10.1016\/j.vaccine.2022.02.043_b0330","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","article-title":"Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero\u00ae to reduce meningococcal group B disease in Germany","volume":"34","author":"Christensen","year":"2016","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2022.02.043_b0335","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1016\/j.vaccine.2014.05.069","article-title":"The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children","volume":"32","author":"Wang","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.02.043_b0340","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2147\/CEOR.S175835","article-title":"Societal costs due to meningococcal disease: a national registry-based study","volume":"10","author":"Gustafsson","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.043_b0345","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10198-019-01129-z","article-title":"Economic evaluation of meningococcal vaccines: considerations for the future","volume":"21","author":"Christensen","year":"2020","journal-title":"Eur J Health Economics"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.043_b0350","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40273-018-0679-5","article-title":"Costs of Invasive Meningococcal Disease: A Global Systematic Review","volume":"36","author":"Wang","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2022.02.043_b0355","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1186\/s12889-015-1885-0","article-title":"Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany\u2013results of a database analysis from May 2010 to April 2012","volume":"15","author":"Ehlken","year":"2015","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.043_b0360","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1186\/s12889-019-7458-x","article-title":"Epidemiology and cost of seasonal influenza in Germany - a claims data analysis","volume":"19","author":"Scholz","year":"2019","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.043_b0365","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s10198-003-0200-7","article-title":"The burden of varicella in Germany","volume":"5","author":"Banz","year":"2004","journal-title":"Eur J Health Econ"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.043_b0370","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2471\/BLT.07.050187","article-title":"Further efforts needed to achieve measles elimination in Germany: results of an outbreak investigation","volume":"87","author":"Wichmann","year":"2009","journal-title":"Bull World Health Organ"},{"issue":"50","key":"10.1016\/j.vaccine.2022.02.043_b0375","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1055\/s-2006-957208","article-title":"Pertussis bei Erwachsenen: H\u00e4ufigkeit, Symptome und Kosten","volume":"131","author":"Riffelmann","year":"2006","journal-title":"Dtsch Med Wochenschr"},{"issue":"17","key":"10.1016\/j.vaccine.2022.02.043_b0380","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.vaccine.2014.01.061","article-title":"Cost-effectiveness of childhood rotavirus vaccination in Germany","volume":"32","author":"Aidelsburger","year":"2014","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.02.043_b0385","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1086\/516716","article-title":"Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study","volume":"195","author":"Giaquinto","year":"2007","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.043_b0390","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10198-014-0624-2","article-title":"Recommendation of rotavirus vaccination and herd effect: a budget impact analysis based on German health insurance data","volume":"16","author":"Karmann","year":"2015","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vaccine.2022.02.043_b0395","doi-asserted-by":"crossref","unstructured":"Abstracts des Kongresses f\u00fcr Kinder- und Jugendmedizin 2019. Monatsschrift Kinderheilkunde 2019; 167(S4): 197\u2013278. https:\/\/doi.org\/10.1007\/s00112-019-0759-4.","DOI":"10.1007\/s00112-019-0759-4"},{"key":"10.1016\/j.vaccine.2022.02.043_b0400","doi-asserted-by":"crossref","first-page":"100103","DOI":"10.1016\/j.lanepe.2021.100103","article-title":"Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: An analysis of national surveillance data during week 1\u20132016 \u2013 week 32\u20132020","volume":"6","author":"Ullrich","year":"2021","journal-title":"The Lancet Regional Health - Europe"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.043_b0405","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","volume":"3","author":"Brueggemann","year":"2021","journal-title":"The Lancet Digital Health"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.043_b0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212908","article-title":"Positive predictive value of the German notification system for infectious diseases: Surveillance data from eight local health departments, Berlin, 2012","volume":"14","author":"Bl\u00fcmel","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.043_b0415","article-title":"Complementing conventional infectious disease surveillance with national health insurance claims data in the Republic of Korea","volume":"9","author":"Jung","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.043_b0420","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-14-147","article-title":"Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods","volume":"14","author":"Gibbons","year":"2014","journal-title":"BMC Public Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2200189X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2200189X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:11:39Z","timestamp":1759403499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2200189X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":84,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0264410X2200189X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and economic burden of meningococcal disease in Germany: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}